PAREXEL PACE™, supports clients with strategies and systems specifically developed for Phase IIIb studies. Our experience spans many therapeutic areas and ranges from single-country studies to those carried across multiple national boundaries and continents. In the past three years alone, PAREXEL has conducted over 120 Phase IIIb clinical trials, treating more than 120,000 patients, at over 17,000 investigator sites worldwide. Recently conducted Phase IIIb trials include a 33,000 patient oncology trial conducted at over 2,900 sites in 29 countries and a 7,600 patient cardiovascular trial conducted at over 550 sites in over 30 countries worldwide.
Whether you need to position a product through comparative studies, develop line extensions or extend label claims, we can help expedite Phase IIIb studies from planning to execution by offering:
In an era in which considerable financial resources are at stake, our broad range of peri-approval services can help sponsors extend their product lifecycle, expand prescribing communities, increase product exposure and maximize return on investment by bridging drug development and commercialization.
For more information contact us
We are a leading global bio/pharmaceutical services organization that helps clients expedite time-to-market through our development and launch services. These include a broad range of clinical development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialization services.